Based upon current literature and our experimental results, we believe that WFA is targeting the NF-κB signaling axis, the UPS, and the ALS in an attempt to mitigate the effects of ovarian cancer in skeletal muscle. This evidence concerns the gene NFKB1 and amyotrophic lateral sclerosis.